Are Peptides Legal? Australia Schedule 4, US FDA, UAE Rules (2026)

The Key Legal Distinction: Intended Use

The legality of peptides is not determined by the compound itself. In virtually every major jurisdiction, what matters is how the peptide is sold, labelled, and used. The same molecule can be legal in one context and illegal in another.

The “research use only” label is not a legal loophole. Regulators in the US, UK, and Australia have pursued enforcement where products were technically labelled for research but clearly intended for human use—evidenced by therapeutic marketing claims, inclusion of syringes/diluent, dosing instructions for self-injection, or user reviews indicating personal administration.

United States — FDA Regulatory Status

The FDA Category System

The FDA classifies bulk drug substances used by compounding pharmacies into two categories:

• Category 1: Substances with sufficient safety data—licensed pharmacies may compound them under a physician’s prescription.
• Category 2: Substances presenting “significant safety risks”—cannot be used in compounding unless FDA authorises through formal rulemaking.

This classification only applies to compounding pharmacies. It does not affect research-use peptides sold for laboratory purposes.

The 2023 Category 2 Reclassification

In late 2023, the FDA moved 19 peptides from Category 1 to Category 2, taking them out of the interim compounding pathway for licensed pharmacies while FDA evaluated safety concerns.^[1] Key examples included:

• BPC-157, TB-500 fragment, Thymosin Alpha-1
• CJC-1295, Ipamorelin, AOD-9604, Selank, Semax
• Injectable GHK-Cu, KPV, MOTS-C, Epitalon, Melanotan II, Dihexa acetate, PEG-MGF, Kisspeptin-10, LL-37, and MK-677

In September 2024, five peptides were removed from Category 2 after nominators withdrew: AOD-9604, CJC-1295, Ipamorelin Acetate, Thymosin Alpha-1, and Selank Acetate.

April 15–16, 2026 FDA Category 2 Removal

FDA’s next formal step came on April 15–16, 2026, when it removed 12 peptides from Category 2 of the 503A Do-Not-Compound list because the nominations were withdrawn.^[2] The removed compounds are BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500.

The change is narrower than many social posts made it sound. It does not approve these peptides as finished drugs, and it does not make open-ended human marketing legal. It lifts the interim 503A compounding restriction because nominations were withdrawn. A Federal Register notice on April 16, 2026 then scheduled the July 23–24, 2026 PCAC meeting to consider seven of them for affirmative 503A Bulks List inclusion.

July 2026 PCAC Review

FDA also announced a July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting to review seven peptides for possible inclusion on the 503A bulks list.^[2] The two-day agenda separates the candidates by clinical context. Day 1: BPC-157 (ulcerative colitis), TB-500 (wound healing), MOTS-c (obesity / osteoporosis), KPV (wound / inflammation). Day 2: Semax (cerebral ischemia / migraine / trigeminal neuralgia), Epitalon (insomnia), DSIP / Emideltide (opioid withdrawal / insomnia / narcolepsy).^[14] That review could shape future compounding access, but it is still separate from FDA approval of finished drugs. For the full breakdown of the schedule, indications, and what each outcome would mean, read the July 2026 PCAC peptide review explainer.

Semaglutide Compounding Crackdown

On February 21, 2025, the FDA resolved the semaglutide shortage, triggering compounding deadlines: 503A pharmacies had until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to stop compounding semaglutide. The Outsourcing Facilities Association filed a lawsuit challenging this determination. For background on approved GLP-1 formulations, see our Rybelsus oral semaglutide guide.

Are Peptides Controlled Substances in the US?

No. Most peptides—including BPC-157, GHK-Cu, and retatrutide—are not DEA-scheduled controlled substances under the Controlled Substances Act. Possession is not a criminal offence under federal drug scheduling law. However, selling them for human consumption constitutes distributing adulterated and misbranded drugs under the Federal Food, Drug, and Cosmetic Act.

Enforcement Cases

The FDA has taken enforcement action against companies selling peptides marketed for human use. Tailor Made Compounding LLC (Kentucky) pleaded guilty to distributing unapproved new drugs including BPC-157, CJC-1295, Ipamorelin, and Selank, resulting in $1.79M forfeiture.^[4] In early 2025, states including Alabama took enforcement action against wellness clinics marketing research-grade peptides as medical treatments.

United Arab Emirates — MoHAP & Research Use

In the UAE, a “For Research Use Only” label does not by itself determine a compound’s legal status or create an approved human-use pathway. MoHAP and the Emirates Drug Establishment regulate pharmaceutical products, while compound-specific controlled-substance, customs, and import rules must be checked separately.

• Regulatory bodies: MoHAP (Ministry of Health and Prevention) and the Emirates Drug Establishment (EDE) oversee pharmaceutical regulation.
• Controlled substances: Federal Decree Law No. 30 of 2021 governs narcotics and psychotropic substances.^[5] Status must be checked compound by compound against the current schedules; a broad “research peptide” label is not a schedule determination.
• Research-use labelling: RUO labelling describes intended laboratory scope; it is not a substitute for product registration, import authorisation, or compound-specific legal review.
• Human-use restriction: Any product marketed for human therapeutic use without MoHAP/EDE registration is considered an unregistered pharmaceutical product.

Research-grade material of this kind is labelled “For Research Use Only” and is not intended for human or veterinary administration. For more on the UAE research landscape, see our UAE peptide research landscape, our Dubai-specific legality brief, and GLP-1 medications in the UAE.

United Kingdom — MHRA Regulatory Position

• Most research peptides (BPC-157, GHK-Cu, TB-500) remain unscheduled under the Misuse of Drugs Act 1971.
• Peptides are legal to buy and sell when supplied for research and development purposes to qualified buyers (laboratories, universities, research facilities).
• The MHRA prohibits peptides being marketed or sold for human consumption or therapeutic use unless licensed as medicines.
• The MHRA has taken enforcement actions where “research use” labels were contradicted by marketing materials, user reviews, or product packaging indicating personal use.

The UK government is expected to reconsider peptide legal status in 2026 as part of a broader strategy to manage novel substances, potentially introducing more stringent distribution requirements.

Australia — TGA & Schedule 4 Classification

Australia has the strictest peptide regulations of any major market.

• BPC-157: Schedule 4 (prescription-only medicine) under the Poisons Standard.^[8] Illegal to possess without a valid prescription. Not approved by TGA for any human indication.
• Semaglutide: As of June 2026, FDA policy (effective October 1, 2024) prohibits pharmacists from compounding GLP-1 receptor agonist products, including semaglutide.
• Tirzepatide (Mounjaro): TGA-registered for type 2 diabetes (December 2022) and chronic weight management (September 2024).
• WADA status: BPC-157 is prohibited under the WADA Prohibited List (category S0: Unapproved Substances). Sport Integrity Australia actively enforces this.
• Penalties: Possession without authorisation carries fines up to AUD $1,975.90 for first offenders. Illegal sale carries up to 2 years imprisonment.

Canada — Health Canada Framework

• Peptides regulated under the Food and Drugs Act and Food and Drug Regulations.
• Peptides intended solely for research purposes are permitted for purchase and use in research labs, provided they are not marketed for human consumption.
• A substance is treated as a drug if sold or represented for treating disease or modifying body functions in humans.
• Health Canada has issued safety alerts for unauthorised injectable peptide products sold online, flagging them as posing serious health risks.

European Union — EMA Framework

• The European Medicines Agency classifies peptides as medicinal products requiring centralised approval for human use.
• Peptides sold as research chemicals are legal when properly labelled and supplied to qualified buyers.
• They cannot be marketed as supplements, cosmetics, or medical treatments without EMA approval.
• Customs agencies in EU member states have seized shipments of unapproved peptides. Regulations vary by member state.
• In December 2025, the EMA published updated guidelines on synthetic peptide manufacture (effective June 2026), though these apply to pharmaceutical manufacturing, not research chemical suppliers.

2026 Peptide Legality — Country Comparison

On phone, swipe sideways to compare all five columns.

Is Retatrutide Legal?

Retatrutide (LY-3437943) is not FDA-approved and is currently in Phase 3 clinical trials under Eli Lilly’s TRIUMPH program. It cannot be legally prescribed, dispensed by a pharmacy, or sold for human consumption in any jurisdiction.

Retatrutide’s investigational status is unchanged by an RUO label: the label does not create regulatory approval, a pharmacy pathway, or authorisation for human or veterinary use. For current trial and regulatory evidence, see the retatrutide approval status tracker; for UAE-specific context, see Retatrutide UAE.

How to Assess Legal Status

• Verify labelling: All research peptides should be clearly marked “For Research Use Only” or “Not for Human or Veterinary Use.”
• Check COA source: A legitimate Certificate of Analysis from an independent third-party lab (e.g., Janoshik Analytical) confirms the product is manufactured and sold as a research compound — our guide on how to verify a Janoshik COA walks through the check.
• Know your jurisdiction: Regulations vary significantly. Australia restricts BPC-157 as Schedule 4; the US does not schedule it under the Controlled Substances Act. Check current official rules before importing, possessing, or transferring a compound.
• Avoid therapeutic claims: Any supplier making claims about treating, curing, or preventing disease is operating outside legal boundaries in every major jurisdiction.
• Document research purpose: Maintain records of your research protocol and intended use, especially when importing peptides across borders.

FDA PCAC meeting concluded July 24, 2026

The FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24 has concluded. The official agenda covered BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon. Committee recommendations are advisory: they are not drug approvals or final agency rules. FDA presentation materials were available at this review, but an official consolidated vote summary or minutes were not retrieved, so this page does not present exact tallies as FDA-confirmed. Source: FDA meeting page and materials.